Ann Intern Med:抗磷脂抗体或是首次心肌梗死的独立危险因素

2018-11-23 佚名 嘉音

在线发表于《Annals of Internal Medicine》杂志上的一项研究显示,抗磷脂抗体(aPLs)和首次心肌梗死(MI)之间存在强而独立的关联,可能是普通人群MI的一个重要的危险因素。

在线发表于《Annals of Internal Medicine》杂志上的一项研究显示,抗磷脂抗体(aPLs)和首次心肌梗死(MI)之间存在强而独立的关联,可能是普通人群MI的一个重要的危险因素。

因为aPLs会出现有无或增减的变化,梗塞事件发生后的6~10周采集血样, aPLs可能是MI组织损伤的一种反应。由于aPLs的存在,例如抗心磷脂或抗β2糖蛋白1(抗β2GPI),患者更容易发生血栓。被诊断为抗磷脂综合征(APS)的患者也具有瓣膜异常的风险。瑞典卡罗林斯卡学院的Elisabet Svenungsson博士认为,此次小样本人群的非标准化测试却显示了aPLs与MI事件相冲突的结果。这一研究发现令人惊奇,相关证据清晰且确凿。未来,我们应该关注这些抗体与MI事件的时间关系。

为了检测MI事件中抗β2GPI、抗心磷脂同位素和抗核抗体出现的频率,研究者在牙周炎及其与冠状动脉疾病(PARKORACE)的关系研究中,连续检测了2010~2014年间瑞士17家医院805例75岁以下(平均年龄62岁,81%为男性)首次因MI住院患者,以及在年龄、性别和种族等变量相匹配的805例对照组患者的相关数据。MI患者在当前吸烟(26% vs 12%),患有风湿性疾病(11% vs 7%)以及慢性阻塞性肺疾病(4% vs 2%)方面高于对照组。与对照组相比,MI患者更有可能有抗心磷脂 IgG (11% vs 1%;P <0.001)和 抗β2GPI IgG抗体(10% vs 1%;P <0.001),病例组和对照组之间的 IgA和IgM抗体无显著差异。

年龄在aPL IgG阳性和IgG阴性的MI患者中没有统计学意义上的差距(63.1岁vs 61.8岁),尽管IgG阳性患者更有可能是女性(26.1% vs 17.9%)和当前吸烟(33.7% vs 25.1%)。在多变量分析中,IgG阳性(OR,7.8;95% CI,4.0~15.3)和当前吸烟(OR,2.6;95% CI,1.9~3.5;两者P<0.001)与MI相关联,然而糖尿病高血压和BMI与MI无关联。

根据悉尼标准,对β2GPI蛋白的特定结构域进行定义,研究者检测了aPL阳性患者和六例APS患者。研究结果显示,MI患者在较少的结构域中有抗体,主要是域IV和V,而APS患者的抗体靶向于血浆蛋白的五个结构域。Svenungsson说:“这可能是早期反应,也可能是一种同类型的扩散,就像你在抗类风湿关节炎抗体中看到的抗瓜氨酸抗体一样。我认为这一发现非常有趣,但这也提出了很多新问题。这些问题有关抗体与结构域之间的时间关系;有关IgG, IgA和IgM同位素;有关于MI时间之前的因果关系。如果人群中有1/10的MI患者有这些抗体,这将是一个重要的问题,或许有助于抗凝治疗”。

直接抗凝药或新型口服抗凝剂(DOACs/NOACs)已经改变了许多房颤和静脉血栓形成患者的治疗方式,但目前还不清楚它们与华法林的对比,华法林是APS患者终身抗凝的金标准。

与华法林相比(12% vs 0%),在狼疮抗凝、抗心磷脂和抗β2GPI抗体三重阳性的高危APS患者的血栓性抗磷脂综合征(RAPP)试验中,利伐沙班由于动脉事件过多而被终止使用。

原始出处:
Grosso G, Sippl N, Kjellström B. et al. Antiphospholipid Antibodies in Patients With Myocardial Infarction. Ann Intern Med. 2018 Oct 23. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-12-23 124adddfm60暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-25 hb2008ye
  5. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 ylzr123

    好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 医者仁心5538

    认真学习了,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1722152, encodeId=8cb21e2215282, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Nov 30 07:08:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037190, encodeId=ee3c203e190cc, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 03 12:08:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356193, encodeId=ccdd35619328, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36002506504, createdName=124adddfm60暂无昵称, createdTime=Sun Dec 23 13:46:02 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609337, encodeId=18fa160933e5e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Nov 25 14:08:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353547, encodeId=14c935354e11, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Nov 24 13:03:46 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353538, encodeId=e8af35353894, content=认真学习了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 24 12:55:54 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353498, encodeId=17ff35349837, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Sat Nov 24 06:26:32 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 深海的鱼

    学习学习学习

    0

相关资讯

Semin Arthritis Rheu:抗磷脂抗体与肾移植

APL与移植物血栓形成、损失和持续时间密切相关,但与移植物功能障碍和排斥反应无关。

综述:神经精神性狼疮研究进展

系统性红斑狼疮(SLE)是一种不明原因的慢性全身性自身免疫炎性疾病。总体发病率为1:2000。男女比例为1:9,育龄期女性多见。SLE累及肺,肾以及中枢神经系统时更为严重,且为主要死因。SLE的神经精神症状是SLE的主要临床表现而非并发症。 神经精神性狼疮(NPSLE)的发病率为21%到95%。其预后高度可变,预后差主要由以下几个原因导致:1 没有规范的标准和定义;2 没有使用确定的标准评价

Heart:抗磷脂抗体与感染性心内膜炎的栓塞事件之间的相关性分析!

由此可见,aCL和抗β2GPI IgM与EE相关,特别是脑部EE,并可能有助于评估IE的栓塞风险。